Effectiveness of Perioperative Radiotherapy With Systemic Therapy on Survival of Squamous Cell Lung Cancer Patients With Pathologic N2
Respirology · 2025
DOI: 10.1111/resp.70078 ↗At a glance
Journal article in Respirology, 2025. Written by Yongzheng Yao and 4 co-authors. Institution: Department of Thoracic Surgery, Miyun District Hospital, Beijing, China. Major MEDLINE topics: Lung Neoplasms, Carcinoma, Squamous Cell. 24 references. Funded by: Major Science and Technology Special Project of Lhasa in 2025, Tibet Autonomous Region Natural Science Foundation Group-based Assisted Medicine Project for Tibet, Beijing Tongzhou District Canal Talent Project (2020-2025).
Topics: Onkologische Pflege
Abstract (original language)
Background and Objective The role of perioperative radiotherapy in squamous cell lung cancer patients with pathologic N2 remains unclear. The purpose of this study was to explore the effectiveness of preoperative radiotherapy (PRRT) and postoperative radiotherapy (PORT) on survival.
Methods
Patients with pathologic N2 stage III squamous cell lung cancer who received PRRT combined with preoperative systemic therapy (PRST) or PORT combined with postoperative systemic therapy (POST) were identified in the Surveillance, Epidemiology, and End Results database from 2000 through 2021. Propensity score matching (PSM) was used for the matching of patients (1:1 ratio). Overall survival (OS) was compared among the different groups by using Kaplan–Meier analysis.
Results
A total of 2132 patients were included and 344 patients were excluded. After PSM, 105 patients received PRST combined with PRRT while 105 patients received PRST alone; 446 patients received POST combined with PORT while 446 patients received POST alone. For PRST combined with/without PRRT, median OS for radiotherapy was 80 months (95% confidence interval [CI], 60 to 121), which was significantly longer than that without radiotherapy (40 months [95% CI, 30 to 70]; p = 0.016); and the hazard ratio for radiotherapy was 0.65 (95% CI, 0.46 to 0.92) compared with no radiotherapy. For POST combined with/without PORT, there was no significant difference between radiotherapy and no radiotherapy for median OS (34 months [95% CI, 30 to 42] for radiotherapy versus 41 months [95% CI, 34 to 51] for no radiotherapy; p = 0.17).
Conclusion
Our results revealed that PRST combined with PRRT significantly improved OS. image
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Thoracic Surgery, Miyun District Hospital, Beijing, China.
- Department of General Medicine, Eastern Medical District of Chinese PLA General Hospital, Beijing, China.
- Department of Oncology, Miyun District Hospital, Beijing, China.
- Pulmonary and Critical Care Medicine Ward, Miyun District Hospital, Beijing, China.
- Department of Thyroid, Breast, Hernia and Thoracic Surgery, Lhasa People's Hospital, Lhasa, Tibet Autonomous Region, China.
- Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
ORCID profiles: Xiaoqing Cao
Funding
- Major Science and Technology Special Project of Lhasa in 2025
- Tibet Autonomous Region Natural Science Foundation Group-based Assisted Medicine Project for Tibet
- Beijing Tongzhou District Canal Talent Project (2020-2025)
Cite
APA
Yao, Y., Liu, C., Pei, F., Zhang, C., & Cao, X. (2025). Effectiveness of Perioperative Radiotherapy With Systemic Therapy on Survival of Squamous Cell Lung Cancer Patients With Pathologic N2. Respirology. https://doi.org/10.1111/resp.70078
Vancouver
Yao Y, Liu C, Pei F, Zhang C, Cao X. Effectiveness of Perioperative Radiotherapy With Systemic Therapy on Survival of Squamous Cell Lung Cancer Patients With Pathologic N2. Respirology. 2025. doi:10.1111/resp.70078
BibTeX
@article{Yao2025,
author = {Yao, Yongzheng and Liu, Chang and Pei, Fei and Zhang, Changqiang and Cao, Xiaoqing},
title = {Effectiveness of Perioperative Radiotherapy With Systemic Therapy on Survival of Squamous Cell Lung Cancer Patients With Pathologic N2},
journal = {Respirology},
year = {2025},
doi = {10.1111/resp.70078}
}
EUVIMED